Forget Vodafone! I’d go for this serial dividend-raiser and its solid business instead

I’d avoid Vodafone plc (LON: VOD) and buy shares in this defensive, growing company to lock in its rising dividend.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Telecommunications giant Vodafone has been struggling to raise its dividend and the shares have been falling. I’d look elsewhere for a rising dividend backed by a decent business.

I wrote in January that Emis Group (LSE: EMIS) has been growing its revenue, normalised earnings, operating cash flow and the dividend for years. There’s a strong balance sheet with a pile of net cash and I reckon the company’s business has some decent defensive characteristics.

Good figures

Operations involve providing software and support services to GP practices, hospitals pharmacies, satellite healthcare centres and “across every major UK healthcare setting.”

And the market likes today’s full-year results report judging by this morning’s uplift in the share price of around 8% as I write.

The figures reveal overall revenue grew 6% during the year and recurring revenue lifted 5%. In terms of the adjusted numbers, net cash from operations moved 10% higher and earnings per share came in flat. The progress showed up on the balance sheet with the firm posting a 12% lift in net cash to £15.6m. This is a positive outcome extending the firm’s record. The directors expressed their approval, and confidence in the outlook, by pushing up the total dividend for the year by 10%.

Chief executive Andy Thorburn said in the report that revenue grew in all the firm’s key segments and much of it can be categorised as ‘recurring’, which I reckon adds to the defensive appeal of the business. The outcome was decent cash generation, which supports the progressive dividend policy and Thorburn thinks the firm is “well positioned” for future expansion.

Planning for growth

The company has been planning and investing for growth and, in 2018, “considerable management time” went into developing the strategy and attracting new talent to the business. The firm made 21 “key senior hires,” which sets it up well for 2019.

Back in January, with the share price around 897p, I said “I’d be happy to dip my toe in the water by buying a few of the company’s shares.” If I’d done so, today’s price close to 1,034p would be showing me a capital gain of just over 15%. However, I think there’s much more potential in Emis and I’d want to tuck some of the shares away for the long haul.

City analysts following the firm have pencilled in earnings increases of around 9% for this year and for 2020. The forward price-to-earnings ratio sits close to 19 two years out, and the predicted dividend yield is running a little under 3.2%. The valuation looks to be up with events, but I reckon the company is worth a premium because of the consistency of its results over several years. To me, Emis is worth keeping a close eye on with a view to buying some of the shares on dips and down-days with a view to holding onto them for the long haul.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any share mentioned. The Motley Fool UK has recommended Emis Group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are Rolls-Royce shares undervalued heading into 2025?

As the new year approaches, Rolls-Royce shares are the top holding of a US fund recommended by Warren Buffett. But…

Read more »

Investing Articles

£20k in a high-interest savings account? It could be earning more passive income in stocks

Millions of us want a passive income, but a high-interest savings account might not be the best way to do…

Read more »

Investing Articles

3 tried and tested ways to earn passive income in 2025

Our writer examines the latest market trends and economic forecasts to uncover three great ways to earn passive income in…

Read more »

Investing Articles

Here’s what £10k invested in the FTSE 100 at the start of 2024 would be worth today

Last week's dip gives the wrong impression of the FTSE 100, which has had a pretty solid year once dividends…

Read more »

Investing Articles

UK REITs: a once-in-a-decade passive income opportunity?

As dividend yields hit 10-year highs, Stephen Wright thinks real estate investment trusts could be a great place to consider…

Read more »

Investing Articles

Is Helium One an amazing penny stock bargain for 2025?

Our writer considers whether to invest in a penny stock that’s recently discovered gas and is now seeking to commercialise…

Read more »

Investing Articles

Here are the 10 BIGGEST investments in Warren Buffett’s portfolio

Almost 90% of Warren Buffett's Berkshire Hathaway portfolio is invested in just 10 stocks. Zaven Boyrazian explores his highest-conviction ideas.

Read more »

Investing Articles

Here’s the stunning BP share price forecast for 2025

The BP share price enters 2025 in poor shape, after a tricky year for energy stocks. Harvey Jones looks at…

Read more »